Skip to main content
. Author manuscript; available in PMC: 2021 Feb 3.
Published in final edited form as: Genet Med. 2020 Aug 3;22(12):2101–2107. doi: 10.1038/s41436-020-0921-3

Table 5.

Gene-specific rates of tumor detection using imaging screening for the total cohort.

Subjects with true positive screens (excluding recurrence) (n) Total subjects (n) Percent positive subjects
SDHA 1 9 11%
SDHB 29 188 15%
SDHC 1 28 4%
SDHD 14 35 40%
SDHAF2 0 3 0.00%
Total 45 263 17%

True positive means tumor was SDHx-related including PGL/PCC, RCC or GIST